Penumbra vs Dr. Reddy's Laboratories
Penumbra (PEN), health care, and Dr. Reddy's Laboratories (RDY), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Penumbra is worth $12.6B on the stock market and Dr. Reddy's Laboratories $12.3B: Penumbra is valued at 2% more. Penumbra trades at 80.4 times earnings and Dr. Reddy's Laboratories at 41.1; operating margins in their latest fiscal years were 13.5% and 15.0%. Over the past year Penumbra's share price has moved +15.3% and Dr. Reddy's Laboratories's +4.85%.
Key facts
- Penumbra market value
- $12.6B
- Dr. Reddy's Laboratories market value
- $12.3B
- Penumbra P/E
- 80.4
- Dr. Reddy's Laboratories P/E
- 41.1
- Penumbra revenue
- $1.4BFY to 2025-12-31
- Dr. Reddy's Laboratories revenue
- $3.6BFY to 2026-03-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | Penumbra | Dr. Reddy's Laboratories |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2026-03-31 |
| Size | ||
| Market cap | $12.6Bhigher | $12.3Blower |
| Revenue | $1.4Blower | $3.6Bhigher |
| Earnings | $177.7Mlower | $456Mhigher |
| Employees | 4,700lower | 27,527higher |
| Total assets | $1.8Blower | $6.2Bhigher |
| Valuation | ||
| P/E | 80.4higher | 41.1lower |
| P/S | 9.0higher | 3.4lower |
| P/B | 7.9 | — |
| Dividend yield | 0.00% | — |
| Profitability | ||
| Operating margin | 13.5%lower | 15.0%higher |
| Balance sheet | ||
| Net assets | $1.4Blower | $4Bhigher |
| Total liabilities | $398.9Mlower | $2.1Bhigher |
| Total debt | — | $193.7M |
| Cash on hand | $186.9Mhigher | $163.5Mlower |
| Price change | ||
| Today | -0.47%lower | +0.61%higher |
| 1 year | +15.3%higher | +4.85%lower |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
Penumbra only (2)
- Paul Tudor Jones0.5%
- Israel Englander0.1%
Dr. Reddy's Laboratories only (0)
None of the tracked investors.
Percentages are each holding's share of that investor's reported portfolio. Who owns PEN · Who owns RDY
More on Penumbra
Further comparisons
Penumbra against its closest peers
Dr. Reddy's Laboratories against its closest peers
Learn
Questions and answers
Which is bigger, Penumbra or Dr. Reddy's Laboratories?
By market value, Penumbra is the larger: $12.6B against $12.3B for Dr. Reddy's Laboratories. By revenue in its latest fiscal year, Dr. Reddy's Laboratories is the larger: $3.6B against $1.4B for Penumbra.
Which has the higher P/E ratio?
Penumbra: 80.4, against 41.1 for Dr. Reddy's Laboratories. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
Dr. Reddy's Laboratories: 15.0%, against 13.5% for Penumbra. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both Penumbra and Dr. Reddy's Laboratories?
None of the tracked superinvestors holds both in their latest 13F filing. 2 hold Penumbra and 0 hold Dr. Reddy's Laboratories.
Cite this page
Funkfolio, “Penumbra vs Dr. Reddy's Laboratories”, data as of 18 November 2026. https://funkfolio.com/compare/pen-vs-rdy
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.